Philadelphia, PA, April 11, 2013 A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.
Traditionally, abstinence has been regarded as the primary treatment goal for alcohol dependence, and current pharmacological treatments for alcoholism are approved only for relapse prevention. However, relapse rates remain high and a goal of abstinence is unacceptable to many patients. To address these concerns and provide opportunities for improved patient outcomes, new evidence-based treatments are necessary.
"Our new findings may mark a true paradigm shift in the treatment of men and women who suffer from alcohol related disorders. While abstinence should be the best bet, a reduction in consumption may be a valuable alternative for the many patients who cannot attain abstinence or are not (yet) capable of doing so," said Dr. Karl Mann at Central Institute of Mental Health in Germany, who led the research.
Mann and his colleagues conducted a clinical trial to investigate the effectiveness of nalmefene in reducing alcohol consumption. They recruited 604 alcohol-dependent patients, half of whom were randomized to receive nalmefene, while the other half received visually-identical placebo pills. Neither patients nor their doctors knew which treatment they were receiving. Patients were instructed to take one tablet on each day they perceived a risk of drinking alcohol, and were followed by the study investigators for 24 weeks.
What they found is promising. Nalmefene was significantly better than placebo in reducing alcohol consumption and it improved patients' clinical status and liver enzymes. It was also generally well-tolerated, with most side effects characterized as mild or moderate and quickly resolved.
"With nalmefene, we seem to be able to 'block the buzz' which
|Contact: Rhiannon Bugno|